Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

An Open-Label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477, a First in Clinic Inhibitor of the p300/CPB Bromodomains, As Monotherapy in Patients with Advanced Haematological Malignancies

Tomasz Knurowski, PhD MD, Karen Clegg, PhD, Nigel Brooks, PhD, Fay Ashby, Neil A Pegg, PhD, William West, PhD, Harriet S Walter, Tim CP Somervaille, MD PhD, Steven Knapper, DM, Andrew Davies, MD PhD

Blood (2019) 134 (Supplement_1): 1266.

https://doi.org/10.1182/blood-2019-124797

Published: 2019

Journal Articles

PKC-Epsilon Overexpression Is Associated with Poor Outcomes in AML and Promotes Chemoresistance and Hematopoietic Stem Cell Quiescence

Rachael Louise Nicholson, BSc, Steven Knapper, DM, Alex Tonks, PhD, Richard L Darley, PhD

Blood (2019) 134 (Supplement_1): 2704.

https://doi.org/10.1182/blood-2019-128184

Published: 2019

Journal Articles

Overexpression or Deficiency of RUNX3 Results in Defective Normal Human Hematopoietic Development Similar to RUNX1-ETO Expression in AML

Ana Catarina Menezes, MSc, BSc, Steven Knapper, DM, Richard L Darley, PhD, Alex Tonks, PhD

Blood (2019) 134 (Supplement_1): 2527.

https://doi.org/10.1182/blood-2019-130798

Published: 2019

Journal Articles

Rapid Elimination of NPM1 Mutant Measurable Residual Disease (MRD) Using Low Intensity Venetoclax-Based Combinations in Acute Myeloid Leukemia (AML)

Blood (2019) 134 (Supplement_1): 2648.

https://doi.org/10.1182/blood-2019-123899

Published: 2019

Journal Articles

Results of a Phase 2 Trial of the Monocyte-Targeted Histone Deacetylase Inhibitor Tefinostat (CHR-2845) in Chronic Myelomonocytic Leukemia (CMML) — the UK Monocle Study

Steven Knapper, DM, Michael Dennis, MD, MRCP, FRCPath, Mark W Drummond, PhDMD, Robert K. Hills, MA, DPhil, MSc, Richard James Dillon, MA, PhD MRCP, FRCPath, Christopher Pocock, MD PhD, Dominic J. Culligan, Paresh Vyas, Daniel Wiseman, MB, ChB, Joanna Zabkiewicz, PhD, Marie Hodges, PhD MSc, Catherine Cargo, MB, FRCPath, Jan Taylor, PhD MSc, BSc, Laura Upton, Melissa Wright, David Bowen, MD PhD

Blood (2018) 132 (Supplement 1): 1818.

https://doi.org/10.1182/blood-2018-99-110356

Published: 2018

Journal Articles

"Function First" Screen of Primary AML Cells Identifies Common and Personalised Therapeutic Targets

Jamshid S Khorashad, MD PhD, Carme Ripoll Fiol, Eva Yebra-Fernandez, MD, Elisabet Nadal-Melsio, MD, Mahroo Karimpoor, PhD, Simone Claudiani, MD, Alistair Reid, BSc, PhD, Steven Knapper, DM, Kikkeri Naresh, Jane Apperley, MB ChB MD, Clinton C. Mason, PhD

Blood (2018) 132 (Supplement 1): 1517.

https://doi.org/10.1182/blood-2018-99-115417

Published: 2018

Journal Articles

Pegylated-Interferon Treatment Is Safe and Efficient for Pregnant Patients with Essential Thrombocythaemia

Yan Beauverd, Arvind Pillai, MBBS, MRCP, FRCPath, Steven Knapper, DM BMBCh FRCPath MRCP, Catherine Cargo, MB MRCP FRCPath, Claire N. Harrison, Susan Robinson

Blood (2015) 126 (23): 1613.

https://doi.org/10.1182/blood.V126.23.1613.1613

Published: 2015

Journal Articles

Integrated Nuclear Proteomics and Transcriptomics Identifies New High Frequency Dysregulated Transcription Factors in AML

Chinmay R Munje, BSc PhD, Andrew J. K. Williamson, BSc, PhD, Samuel Taylor, BSc, PhD, Robert K. Hills, MA, MSc, DPhil, Steven Knapper, DM BMBCh, Alan K. Burnett, MD, Andrew Pierce, BSc, PhD, Anthony Whetton, BSc, PhD, Richard L. Darley, BSc PhD, Alex Tonks, BSc PhD

Blood (2014) 124 (21): 3554.

https://doi.org/10.1182/blood.V124.21.3554.3554

Published: 2014

Journal Articles

Pacritinib Suppresses Leukemic Outgrowth from FLT3-ITD Positive Stroma-Adherent Primary AML Cells

Ceri Marrin, MBBCh, Gareth Edwards, PhD, Steven Knapper, DM BMBCh, Alan K. Burnett, MDFRCP, Joanna Zabkiewicz, PhD, Caroline Alvares, MB BS PhD

Blood (2014) 124 (21): 270.

https://doi.org/10.1182/blood.V124.21.270.270

Published: 2014

Journal Articles

CD200 and PD1-L1 in AML Are Associated with Expanded PD-1 + Late Differentiated CD8 + T Cells and a Decreased CD4:CD8 Ratio: a New Link Between Distinct Immunosuppressive Pathways

Steven Coles, PhD, Marie N Gilmore, PhD, Reiss Reid, PhD, Steven Knapper, DM BMBCh, Alan K. Burnett, MDFRCP, Steven Man, PhD, Alex Tonks, PhD, Richard L Darley, PhD

Blood (2014) 124 (21): 992.

https://doi.org/10.1182/blood.V124.21.992.992

Published: 2014

Journal Articles

A Subpopulation of Blasts with Attenuated p38 MAPK Response Is Seen in Virtually All AML Patients and AML Cell Lines and Is Defined By Cells with Augmented Lipid-Associated Anti-Oxidant Defense

Paul S. Hole, PhD, Sara Davies, MSc, Chinmay R Munje, BSc PhD, Sandra Kreuser, BSc, Robert K. Hills, MA MSc DPhil, Nader Omidvar, PhD, Steven Knapper, DM BMBCh, Alan K. Burnett, MDFRCP, Alex Tonks, BSc PhD, Richard L. Darley, BSc PhD

Blood (2014) 124 (21): 785.

https://doi.org/10.1182/blood.V124.21.785.785

Published: 2014

Journal Articles

A Randomised Comparison of the Sequential Addition of the FLT3 Inhibitor Lestaurtinib (CEP701) to Standard First Line Chemotherapy for FLT3-Mutated Acute Myeloid Leukemia: The UK Experience

Steven Knapper, DM, Robert K Hills, MA MSc DPhil, James D Cavenagh, MD, Lars Kjeldsen, MDPhD, Ann E. Hunter, MBBS, Richard E Clark, MBBS MD, Michael Dennis, MD, Donald Milligan, MD, Mark J Levis, MDPhD, Nigel Russell, Alan K. Burnett, MD

Blood (2014) 124 (21): 3736.

https://doi.org/10.1182/blood.V124.21.3736.3736

Published: 2014

Journal Articles

Response To Ruxolitinib In Patients With Intermediate-1, Intermediate-2 and High-Risk Myelofibrosis: Interim Results Of The UK Robust Trial

Claire N Harrison, DM, FRCP, FRCPath, Richard E Clark, MD, Joseph Chacko, Steven Knapper, DM BMBCh, John Yin, MD, Dragana Milojkovic, PhD, Mira Farquharson, FRCPath, MBChB, MRCP, Sahra Ali, FRCPath, FRCP, BM, MRCP, MRCPath, Mamta K Garg, MD, FRCP, FRCPath, Christopher Andrews, PhD, Cstat, CSci, Susan M Graham, PhD, Adam J. Mead, M.D., Ph.D.

Blood (2013) 122 (21): 2826.

https://doi.org/10.1182/blood.V122.21.2826.2826

Published: 2013

Journal Articles

Midostaurin a Multi-Targeted Oral Kinase Inhibitor in Systemic Mastocytosis: Report of An Open-Label Compassionate Use Program in the United Kingdom

Steven Knapper, DM MRCP FRCPath, Jonathan Cullis, Mark W. Drummond, PhD, FRCPath, MB, CHB, Roger Evely, Tamara Everington, Christine Hoyle, Lorna McLintock, MBChB, MD, MRCP, FRCPath, Christopher Poynton, DM, FRCP, FRCPath, Deepti Radia, MD

Blood (2011) 118 (21): 5145.

https://doi.org/10.1182/blood.V118.21.5145.5145

Published: 2011

Journal Articles

The Efficacy of the FLT3 Inhibitor Lestaurtinib in AML Depends on Adequate Plasma Inhibitory Activity (PIA), and Is Unaffected by Rising FLT Ligand Levels: An Update of the NCRI AML15 & 17 Trials

Steven Knapper, DM MRCP FRCPath, Paul White, PhD, Mark J. Levis, MD, PhD, Robert K Hills, MA, MSc, DPhil, Nigel H. Russell, MD, Alan Burnett, MD, ChB, FRCP, FRCPath, FMedSci

Blood (2011) 118 (21): 421.

https://doi.org/10.1182/blood.V118.21.421.421

Published: 2011

Journal Articles

L-Gossypol Has Significant In Vitro Activity Against Primary Acute Myeloid Leukaemia Cells, Inducing Apoptosis through the Intrinsic Pathway.

Hani Y. Osman, MD, Steven Knapper, DM, Alan K. Burnett, MD

Blood (2007) 110 (11): 4180.

https://doi.org/10.1182/blood.V110.11.4180.4180

Published: 2007

NARROW

An Open-Label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477, a First in Clinic Inhibitor of the p300/CPB Bromodomains, As Monotherapy in Patients with Advanced Haematological Malignancies

PKC-Epsilon Overexpression Is Associated with Poor Outcomes in AML and Promotes Chemoresistance and Hematopoietic Stem Cell Quiescence

Overexpression or Deficiency of RUNX3 Results in Defective Normal Human Hematopoietic Development Similar to RUNX1-ETO Expression in AML

Rapid Elimination of NPM1 Mutant Measurable Residual Disease (MRD) Using Low Intensity Venetoclax-Based Combinations in Acute Myeloid Leukemia (AML)

Results of a Phase 2 Trial of the Monocyte-Targeted Histone Deacetylase Inhibitor Tefinostat (CHR-2845) in Chronic Myelomonocytic Leukemia (CMML) — the UK Monocle Study

"Function First" Screen of Primary AML Cells Identifies Common and Personalised Therapeutic Targets

Pegylated-Interferon Treatment Is Safe and Efficient for Pregnant Patients with Essential Thrombocythaemia

Integrated Nuclear Proteomics and Transcriptomics Identifies New High Frequency Dysregulated Transcription Factors in AML

Pacritinib Suppresses Leukemic Outgrowth from FLT3-ITD Positive Stroma-Adherent Primary AML Cells

CD200 and PD1-L1 in AML Are Associated with Expanded PD-1 + Late Differentiated CD8 + T Cells and a Decreased CD4:CD8 Ratio: a New Link Between Distinct Immunosuppressive Pathways

A Subpopulation of Blasts with Attenuated p38 MAPK Response Is Seen in Virtually All AML Patients and AML Cell Lines and Is Defined By Cells with Augmented Lipid-Associated Anti-Oxidant Defense

A Randomised Comparison of the Sequential Addition of the FLT3 Inhibitor Lestaurtinib (CEP701) to Standard First Line Chemotherapy for FLT3-Mutated Acute Myeloid Leukemia: The UK Experience

Response To Ruxolitinib In Patients With Intermediate-1, Intermediate-2 and High-Risk Myelofibrosis: Interim Results Of The UK Robust Trial

Midostaurin a Multi-Targeted Oral Kinase Inhibitor in Systemic Mastocytosis: Report of An Open-Label Compassionate Use Program in the United Kingdom

The Efficacy of the FLT3 Inhibitor Lestaurtinib in AML Depends on Adequate Plasma Inhibitory Activity (PIA), and Is Unaffected by Rising FLT Ligand Levels: An Update of the NCRI AML15 & 17 Trials

L-Gossypol Has Significant In Vitro Activity Against Primary Acute Myeloid Leukaemia Cells, Inducing Apoptosis through the Intrinsic Pathway.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only